Does the media favor COG or KOO?

In the previous week, Kooth had 1 more articles in the media than Cambridge Cognition. MarketBeat recorded 2 mentions for Kooth and 1 mentions for Cambridge Cognition. Kooth's average media sentiment score of 1.27 beat Cambridge Cognition's score of 0.00 indicating that Kooth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cambridge Cognition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kooth 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INHC or COG?

Cambridge Cognition has a consensus price target of GBX 56, suggesting a potential upside of 60.32%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Cambridge Cognition is more favorable than Induction Healthcare Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Induction Healthcare Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate RENX or COG?

Cambridge Cognition has a consensus price target of GBX 56, suggesting a potential upside of 60.32%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Renalytix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renalytix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend FDBK or COG?

Cambridge Cognition has a consensus target price of GBX 56, suggesting a potential upside of 60.32%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Feedback. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Feedback 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable valuation & earnings, COG or IQAI?

IQ-AI has lower revenue, but higher earnings than Cambridge Cognition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cambridge Cognition £9.40M 1.73 -£1.58M -£3.90 N/A IQ-AI £538.19K 3.30 N/A N/A N/A

Is COG or IQAI more profitable?

Cambridge Cognition has a net margin of -17.82% compared to IQ-AI's net margin of -77.52%. Cambridge Cognition's return on equity of -62.89% beat IQ-AI's return on equity. Company Net Margins Return on Equity Return on Assets Cambridge Cognition -17.82% -62.89% -0.30% IQ-AI -77.52% -140.75% -22.03%

Cambridge Cognition (COG) Competitors

GBX 34.93 +0.93 (+2.74%)

As of 06/26/2026 10:27 AM Eastern

Compare

COG vs. KOO, INHC, RENX, FDBK, and IQAI

Should you buy Cambridge Cognition stock or one of its competitors? MarketBeat compares Cambridge Cognition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cambridge Cognition include Kooth (KOO), Induction Healthcare Group (INHC), Renalytix (RENX), Feedback (FDBK), and IQ-AI (IQAI). These companies are all part of the "health information services" industry.

How does Cambridge Cognition compare to Kooth?

Cambridge Cognition (LON:COG) and Kooth (LON:KOO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Cambridge Cognition has a beta of 0.737, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Kooth has a beta of 1.298, suggesting that its stock price is 30% more volatile than the broader market.

Cambridge Cognition presently has a consensus target price of GBX 56, suggesting a potential upside of 60.32%. Kooth has a consensus target price of GBX 330, suggesting a potential upside of 110.19%. Given Kooth's higher possible upside, analysts clearly believe Kooth is more favorable than Cambridge Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Kooth had 1 more articles in the media than Cambridge Cognition. MarketBeat recorded 2 mentions for Kooth and 1 mentions for Cambridge Cognition. Kooth's average media sentiment score of 1.27 beat Cambridge Cognition's score of 0.00 indicating that Kooth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cambridge Cognition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kooth	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kooth has higher revenue and earnings than Cambridge Cognition. Cambridge Cognition is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cambridge Cognition	£9.40M	1.73	-£1.58M	-£3.90	N/A
Kooth	£63.29M	0.90	£4.00M	£7.00	22.43

15.9% of Cambridge Cognition shares are held by institutional investors. Comparatively, 21.0% of Kooth shares are held by institutional investors. 3.3% of Cambridge Cognition shares are held by company insiders. Comparatively, 30.4% of Kooth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kooth has a net margin of 4.12% compared to Cambridge Cognition's net margin of -17.82%. Kooth's return on equity of 8.84% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cambridge Cognition	-17.82%	-62.89%	-0.30%
Kooth	4.12%	8.84%	10.12%

Summary

Kooth beats Cambridge Cognition on 14 of the 15 factors compared between the two stocks.

How does Cambridge Cognition compare to Induction Healthcare Group?

Induction Healthcare Group (LON:INHC) and Cambridge Cognition (LON:COG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

In the previous week, Cambridge Cognition had 1 more articles in the media than Induction Healthcare Group. MarketBeat recorded 1 mentions for Cambridge Cognition and 0 mentions for Induction Healthcare Group. Induction Healthcare Group's average media sentiment score of 0.00 equaled Cambridge Cognition'saverage media sentiment score.

Company	Overall Sentiment
Induction Healthcare Group	Neutral
Cambridge Cognition	Neutral

Induction Healthcare Group has a beta of -0.41, indicating that its stock price is 141% less volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.737, indicating that its stock price is 26% less volatile than the broader market.

46.3% of Induction Healthcare Group shares are owned by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are owned by institutional investors. 54.6% of Induction Healthcare Group shares are owned by insiders. Comparatively, 3.3% of Cambridge Cognition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cambridge Cognition has lower revenue, but higher earnings than Induction Healthcare Group. Cambridge Cognition is trading at a lower price-to-earnings ratio than Induction Healthcare Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Induction Healthcare Group	£12.57M	0.72	-£5.12M	-£5.54	N/A
Cambridge Cognition	£9.40M	1.73	-£1.58M	-£3.90	N/A

Cambridge Cognition has a net margin of -17.82% compared to Induction Healthcare Group's net margin of -23.86%. Induction Healthcare Group's return on equity of -14.58% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Induction Healthcare Group	-23.86%	-14.58%	-7.32%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

Cambridge Cognition has a consensus price target of GBX 56, suggesting a potential upside of 60.32%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Cambridge Cognition is more favorable than Induction Healthcare Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Induction Healthcare Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Cambridge Cognition beats Induction Healthcare Group on 10 of the 15 factors compared between the two stocks.

How does Cambridge Cognition compare to Renalytix?

Renalytix (LON:RENX) and Cambridge Cognition (LON:COG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Cambridge Cognition has a consensus price target of GBX 56, suggesting a potential upside of 60.32%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Renalytix has a beta of 1.808, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.737, suggesting that its stock price is 26% less volatile than the broader market.

Cambridge Cognition has a net margin of -17.82% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Renalytix	-680.00%	274.67%	-93.54%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	£3.30M	2.49	-£109.93M	-£4.00	N/A
Cambridge Cognition	£9.40M	1.73	-£1.58M	-£3.90	N/A

In the previous week, Cambridge Cognition had 1 more articles in the media than Renalytix. MarketBeat recorded 1 mentions for Cambridge Cognition and 0 mentions for Renalytix. Renalytix's average media sentiment score of 0.00 equaled Cambridge Cognition'saverage media sentiment score.

Company	Overall Sentiment
Renalytix	Neutral
Cambridge Cognition	Neutral

14.0% of Renalytix shares are held by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are held by institutional investors. 5.1% of Renalytix shares are held by company insiders. Comparatively, 3.3% of Cambridge Cognition shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cambridge Cognition beats Renalytix on 10 of the 15 factors compared between the two stocks.

How does Cambridge Cognition compare to Feedback?

Feedback (LON:FDBK) and Cambridge Cognition (LON:COG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Feedback has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.737, suggesting that its stock price is 26% less volatile than the broader market.

Cambridge Cognition has higher revenue and earnings than Feedback. Cambridge Cognition is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Feedback	£849.62K	3.63	-£10.84M	-£15.74	N/A
Cambridge Cognition	£9.40M	1.73	-£1.58M	-£3.90	N/A

In the previous week, Cambridge Cognition had 1 more articles in the media than Feedback. MarketBeat recorded 1 mentions for Cambridge Cognition and 0 mentions for Feedback. Feedback's average media sentiment score of 0.00 equaled Cambridge Cognition'saverage media sentiment score.

Company	Overall Sentiment
Feedback	Neutral
Cambridge Cognition	Neutral

Cambridge Cognition has a consensus target price of GBX 56, suggesting a potential upside of 60.32%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Feedback.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Feedback	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

34.7% of Feedback shares are held by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are held by institutional investors. 8.0% of Feedback shares are held by insiders. Comparatively, 3.3% of Cambridge Cognition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cambridge Cognition has a net margin of -17.82% compared to Feedback's net margin of -845.25%. Cambridge Cognition's return on equity of -62.89% beat Feedback's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Feedback	-845.25%	-135.17%	-22.99%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

Summary

Cambridge Cognition beats Feedback on 10 of the 15 factors compared between the two stocks.

How does Cambridge Cognition compare to IQ-AI?

Cambridge Cognition (LON:COG) and IQ-AI (LON:IQAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

15.9% of Cambridge Cognition shares are owned by institutional investors. 3.3% of Cambridge Cognition shares are owned by company insiders. Comparatively, 66.0% of IQ-AI shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cambridge Cognition has a beta of 0.737, meaning that its share price is 26% less volatile than the broader market. Comparatively, IQ-AI has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market.

Cambridge Cognition currently has a consensus price target of GBX 56, suggesting a potential upside of 60.32%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cambridge Cognition is more favorable than IQ-AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
IQ-AI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cambridge Cognition has a net margin of -17.82% compared to IQ-AI's net margin of -77.52%. Cambridge Cognition's return on equity of -62.89% beat IQ-AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cambridge Cognition	-17.82%	-62.89%	-0.30%
IQ-AI	-77.52%	-140.75%	-22.03%

IQ-AI has lower revenue, but higher earnings than Cambridge Cognition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cambridge Cognition	£9.40M	1.73	-£1.58M	-£3.90	N/A
IQ-AI	£538.19K	3.30	N/A	N/A	N/A

In the previous week, Cambridge Cognition had 1 more articles in the media than IQ-AI. MarketBeat recorded 1 mentions for Cambridge Cognition and 0 mentions for IQ-AI. Cambridge Cognition's average media sentiment score of 0.00 equaled IQ-AI'saverage media sentiment score.

Company	Overall Sentiment
Cambridge Cognition	Neutral
IQ-AI	Neutral

Summary

Cambridge Cognition beats IQ-AI on 10 of the 13 factors compared between the two stocks.

Get Cambridge Cognition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COG vs. The Competition

Export

Metric	Cambridge Cognition	Health Information Services Industry	Medical Sector	LON Exchange
Market Cap	£16.26M	£355.13M	£6.71B	£2.77B
Dividend Yield	N/A	5.61%	2.67%	6.16%
P/E Ratio	-8.96	254.90	25.77	366.66
Price / Sales	1.73	132.49	555.19	85,978.62
Price / Cash	4.31	47.14	46.99	27.87
Price / Book	4.81	7.43	10.77	7.76
Net Income	-£1.58M	-£22.78M	£3.57B	£5.89B
7 Day Performance	0.09%	0.49%	3.17%	-0.75%
1 Month Performance	-0.20%	1.49%	1.86%	-1.28%
1 Year Performance	5.88%	-9.98%	34.38%	65.91%

Cambridge Cognition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COG Cambridge Cognition	1.198 of 5 stars	GBX 34.93 +2.7%	GBX 56 +60.3%	+2.7%	£16.26M	£9.40M	N/A	80	News Coverage
KOO Kooth	3.1946 of 5 stars	GBX 155 -1.6%	GBX 330 +112.9%	-15.8%	£56.22M	£63.29M	22.14	478	News Coverage
INHC Induction Healthcare Group	N/A	GBX 9.75 flat	N/A	+0.0%	£9.00M	£12.57M	N/A	74
RENX Renalytix	N/A	GBX 1.87 -1.6%	N/A	-73.9%	£8.17M	£3.30M	N/A	102	Gap Up
FDBK Feedback	N/A	GBX 7.40 flat	N/A	-49.7%	£3.24M	£849.62K	N/A	24

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:COG) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cambridge Cognition (COG) Competitors

COG vs. KOO, INHC, RENX, FDBK, and IQAI

How does Cambridge Cognition compare to Kooth?

Summary

How does Cambridge Cognition compare to Induction Healthcare Group?

Summary

How does Cambridge Cognition compare to Renalytix?

Summary

How does Cambridge Cognition compare to Feedback?

Summary

How does Cambridge Cognition compare to IQ-AI?

Summary

Media Sentiment Over Time

COG vs. The Competition

Cambridge Cognition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cambridge Cognition (COG) Competitors

COG vs. KOO, INHC, RENX, FDBK, and IQAI

How does Cambridge Cognition compare to Kooth?

Which has more volatility and risk, COG or KOO?

Do analysts rate COG or KOO?

Does the media favor COG or KOO?

Which has preferable earnings and valuation, COG or KOO?

Do insiders & institutionals have more ownership in COG or KOO?

Is COG or KOO more profitable?

Summary

How does Cambridge Cognition compare to Induction Healthcare Group?

Does the media prefer INHC or COG?

Which has more risk and volatility, INHC or COG?

Do insiders and institutionals hold more shares of INHC or COG?

Which has preferable valuation & earnings, INHC or COG?

Is INHC or COG more profitable?

Do analysts rate INHC or COG?

Summary

How does Cambridge Cognition compare to Renalytix?

Do analysts rate RENX or COG?

Which has more volatility and risk, RENX or COG?

Is RENX or COG more profitable?

Which has higher valuation & earnings, RENX or COG?

Does the media refer more to RENX or COG?

Do insiders & institutionals have more ownership in RENX or COG?

Summary

How does Cambridge Cognition compare to Feedback?

Which has more volatility & risk, FDBK or COG?

Which has preferable earnings and valuation, FDBK or COG?

Does the media refer more to FDBK or COG?

Do analysts recommend FDBK or COG?

Do insiders and institutionals hold more shares of FDBK or COG?

Is FDBK or COG more profitable?

Summary

How does Cambridge Cognition compare to IQ-AI?

Do insiders & institutionals have more ownership in COG or IQAI?

Which has more risk & volatility, COG or IQAI?

Do analysts prefer COG or IQAI?

Is COG or IQAI more profitable?

Which has preferable valuation & earnings, COG or IQAI?

Does the media refer more to COG or IQAI?

Summary

Media Sentiment Over Time

COG vs. The Competition

Cambridge Cognition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools